Physician profile
Steven L Smith
NPI 1598847949
$640.30
in general payments reported to CMS, 2019-2025
12 companies · $51.80 in 2025
The $51.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.03 · 2020: $125 · 2021: $201 · 2022: $44.38 · 2023: $77.12 · 2024: $130 · 2025: $51.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $259.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $155.83 | 2021 | |
| Lilly USA, LLC | $134.88 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $115.70 | 2022-2025 | Dupixent |
| Sun Pharmaceutical Industries INC. | $56.50 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.11 | 2020-2022 | |
| Amgen INC. | $35.61 | 2024-2025 | Evenity, Otezla, Repatha |
| Abbvie INC. | $27.41 | 2023 | Vraylar |
| Glaxosmithkline, LLC. | $16.45 | 2023 | Trelegy Ellipta |
| Genentech USA, INC. | $14.65 | 2021 | |
| Exact Sciences Corporation | $14.07 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $13.07 | 2023 | Farxiga |
| Novo Nordisk INC | $12.02 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.